Stock comparison
IDEXX Laboratories
Zoetis
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
ZTS
Zoetis
Market cap
$31.17B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | ZTS | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 57C | IDXX |
| Benjamin Graham | 72B | 62C | IDXX |
| Philip Fisher | 67B | 53C | IDXX |
| Peter Lynch | 63C | 34F | IDXX |
| Joel Greenblatt | 75B | 35D | IDXX |
| Charlie Munger | 79B | 61C | IDXX |
| Terry Smith | 76B | 65B | IDXX |
Side-by-side metrics
| Metric | IDXX | ZTS |
|---|---|---|
| Market cap | $42.11B | $31.17B |
| P/E (TTM) | 39.0x | 11.9x |
| EV/EBIT | 31.6x | 10.8x |
| ROIC (TTM) | 40.66% | 21.79% |
| Gross margin | 62.05% | 70.75% |
| Net margin | 24.63% | 27.79% |
| Revenue CAGR 5y | 7.56% | 5.04% |
| EPS CAGR 5y | 10.79% | 8.88% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 2.77% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 21.79%+46%
- Revenue CAGR 5y7.56%vs 5.04%+33%
- Market cap$42.11Bvs $31.17B+26%
- EPS CAGR 5y10.79%vs 8.88%+18%
ZTS leads on
- Dividend yield2.77%vs 0.0%+100%
- Debt / Equity0.1xvs 0.7x+91%
- P/E (TTM)11.9xvs 39.0x+70%
- EV/EBIT10.8xvs 31.6x+66%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.